Chemotherapy Adjuvant Humans Liquid Biopsy Muscles Neoplasm Invasiveness Prospective Studies *Urinary Bladder Neoplasms/drug therapy Cell-free DNA Circulating tumor cells Liquid biopsies Muscle-invasive bladder cancer Perioperative therapy

Animals Biological Availability Clinical Trials as Topic Flavonoids/pharmacology/*therapeutic use Flavonols/pharmacology/*therapeutic use Humans Inhibitory Concentration 50 Kaempferols/pharmacology/*therapeutic use Male Models Animal Prostatic Neoplasms/*drug therapy Urinary Bladder Neoplasms/*drug therapy bladder cancer fisetin kaempferol myricetin prostate cancer

Cystoscopy/*methods Feasibility Studies Humans Liquid Biopsy/methods Sensitivity and Specificity *Spectrum Analysis Raman Urinary Bladder/diagnostic imaging/*pathology Urinary Bladder Neoplasms/*diagnosis/pathology/urine Urine/cytology Bladder cancer Raman spectroscopy diagnosis meta-analysis optical

Bladder cancer complications cystectomy frailty mortality organisation regarding the material discussed in the manuscript.

external thermal field thermotherapy hyperthermic intravesical chemotherapy meta-analysis non-muscle invasive bladder cancer normal temperature intravesical chemotherapy thermal intravesical chemotherapy

Carcinoma Transitional Cell/*classification/*genetics/mortality Humans Predictive Value of Tests Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*classification/*genetics/mortality Bladder cancer Molecular classification Molecular subtype Prognosis Progression Urothelial carcinoma

Biomarkers Tumor/*analysis Carcinoma Transitional Cell/*chemistry/*drug therapy Humans Neoadjuvant Therapy Prognosis Urinary Bladder Neoplasms/*chemistry/*drug therapy Biomarkers Nac Neoadjuvant systemic therapy Ucb bladder cancer systematic review

Endoscopic bladder cancer follow-up surveillance form (available at http://dx.doi.org/10.21037/tau-20-1363). The series “Expectant Management in Genitourinary Malignancies (Prostate Bladder Kidney)” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Animals Diabetes Mellitus/*physiopathology Disease Progression Humans Obesity/*complications Urinary Bladder Neoplasms/etiology/*pathology all-cause mortality cancer specific mortality diabetes disease recurrence obesity overweight urinary bladder cancer commercial or financial relationships that could be construed as a potential conflict of interest.

Quality of life (QoL) bladder cancer non-muscle invasive bladder cancer (NMIBC) surveillance form (available at http://dx.doi.org/10.21037/tau-20-1333). The series “Expectant Management in Genitourinary Malignancies (Prostate Bladder Kidney)” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Carcinoma Transitional Cell/*drug therapy Humans Prognosis Receptors Fibroblast Growth Factor/*antagonists & inhibitors Urinary Bladder Neoplasms/*drug therapy Bladder cancer Fgfr FGFR inhibitors Fgfr3 Progression Urothelial carcinoma

Carcinoma in Situ/*diagnosis/*therapy Humans Treatment Outcome Urinary Bladder Neoplasms/*diagnosis/*therapy Bladder cancer Carcinoma in situ Non–muscle-invasive bladder cancer

Cystectomy/*methods Humans Survival Analysis Urinary Bladder Neoplasms/mortality/*surgery Bladder cancer Delay Radical cystectomy Survival

Cystoscopy/*methods Humans *Microscopy Confocal Urinary Bladder Neoplasms/*pathology Bladder cancer Confocal laser endomicroscopy Diagnostic performance Meta-analysis

Adjuvants Immunologic/therapeutic use BCG Vaccine/therapeutic use Evidence-Based Medicine Humans Neoplasm Invasiveness Neoplasm Recurrence Local/*therapy Treatment Outcome Urinary Bladder Neoplasms/pathology/*therapy Bacillus Calmette-Guerin unresponsive Bladder preservation therapy Bladder sparing Non–muscle-invasive bladder cancer

Aged *Diet Dietary Fiber/*administration & dosage Female Humans Male Middle Aged Prospective Studies Risk Factors Urinary Bladder Neoplasms/*prevention & control *Whole Grains bladder cancer cohort study dietary fiber dose-response analysis grain

Aged *Brachytherapy Combined Modality Therapy Disease-Free Survival Female Humans Male Middle Aged Neoplasm Recurrence Local *Urinary Bladder Neoplasms/mortality/pathology/radiotherapy external beam radiotherapy interstitial brachytherapy muscle-invasive bladder cancer organ preservation

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant/methods Cisplatin/therapeutic use Clinical Decision-Making/methods *Cystectomy Disease-Free Survival Female Humans Male Neoadjuvant Therapy/methods Neoplasm Recurrence Local/*epidemiology/pathology/prevention & control Neoplasm Staging Patient Selection *Sex Factors Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/mortality/pathology/*therapy Adjuvant chemotherapy Bladder cancer Gender Meta-analysis Neoadjuvant chemotherapy

Administration Intravesical Antibiotics Antineoplastic/*administration & dosage Antimetabolites Antineoplastic/*administration & dosage Deoxycytidine/administration & dosage/*analogs & derivatives Humans Mitomycin/*administration & dosage Neoplasm Invasiveness Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Gemcitabine Bladder cancer Meta-analysis Mitomycin Systematic evaluation

Humans Neoplasm Recurrence Local/epidemiology/prevention & control Peer Review Prospective Studies Urinary Bladder *Urinary Bladder Neoplasms/surgery bladder cancer intravesical chemotherapy irrigation randomized controlled trial recurrence